DVA · NYSE
DVA · NYSE
187.43 USD
-5.88 (-3.04%)
No new catalyst: DaVita was down about 6.9%, deeper than the earlier pre-market decline, and trading volume turned unusually heavy. Investors continued selling after DaVita narrowed full-year adjusted operating-income and EPS guidance because higher U.S. dialysis technology spending raised costs source; the broader U.S. risk-off session added pressure source.
No new catalyst: DaVita was down about 6.9%, deeper than the earlier pre-market decline, and trading volume turned unusually heavy. Investors continued selling after DaVita narrowed full-year adjusted operating-income and EPS guidance because higher U.S. dialysis technology spending raised costs source; the broader U.S. risk-off session added pressure source.